The rule’s central change
A federal court blocked a rule that would have expanded access to discounted prices under the 340B Drug Discount Program for certain uses of orphan drugs. U.S. District Judge Rudolph Contreras ruled that the Health Resources and Services Administration, or HRSA, did not have authority to adopt that interpretation.
The dispute concerned a legislative exception for orphan drugs. The exception removed orphan drugs from 340B pricing structures. HRSA’s final rules took effect late last year, as discussed in an earlier article on HRSA’s 340B orphan drug exception, and interpreted the exception more narrowly. Under the agency’s interpretation, a drug could qualify for 340B pricing when it was prescribed for a non-orphan purpose.
That approach made the condition being treated central to discount eligibility. The same orphan drug could qualify for a discount in one case and fail to qualify in another. The result would depend on the condition for which the drug was prescribed.
The rule therefore sought to make discounted pricing available when an orphan drug was used for a purpose other than treating the rare condition connected to its orphan designation. HRSA attempted to require that pricing treatment through its interpretation of the statutory exception.
The court’s ruling prevents that interpretation from controlling. The court treated the exception as a limit on HRSA’s authority rather than as a provision the agency could revise through regulation.
The authority question
The Pharmaceutical Research and Manufacturers of America filed a lawsuit seeking to stop enforcement of the rule. The industry group argued that HRSA had exceeded the authority granted to it by interpreting the statutory exception in a way that expanded access to discounts.
Judge Contreras agreed. His ruling stated that courts cannot give an agency’s regulatory goals priority over requirements established by Congress. The issue was whether HRSA could create broader access to discounts without authority in the governing law.
That distinction affects how agencies administer pricing programs. Regulations can explain how statutory language applies in daily operations, but an agency’s role in running a program does not automatically allow it to alter a restriction created by Congress.
In this case, the court concluded that HRSA could not effectively rewrite the orphan drug exception through regulation. The injunction prevents the government from requiring the disputed pricing treatment under the blocked rule.
The ruling therefore concerns the source of the agency’s authority, rather than only the details of 340B pricing. HRSA may administer the program, but the court found that its authority did not extend to changing the reach of the statutory exception in this way.
Why indication-based pricing matters
The decision shows how the condition being treated can affect prescription drug pricing. In the 340B dispute, that condition determined whether an orphan drug could receive a statutory discount. Similar questions can arise whenever a pricing rule changes according to the indication attached to a prescription.
The diagnosis can therefore affect more than clinical treatment. It can also become a pricing factor. A claim may be processed differently when the condition changes which pricing rule applies. Comparisons must account for the circumstances connected to a prescription instead of relying on the product name alone as the full explanation for its price. A comparison of Ozempic pricing by route reflects the same need to examine the details behind a prescription.
The 340B dispute involved an indication-based distinction tied to eligibility for a statutory discount. HRSA’s rule would have treated non-orphan use as a reason to apply the discount even though the product still had orphan status. The court rejected the agency’s authority to make that change through the challenged rule.
The case also shows why the legal source of a pricing rule affects what an agency can do. When Congress creates an exception, the agency may have limited room to adjust its application for policy reasons. Changes that affect discount eligibility must remain within the authority provided by Congress.
What happens next
The ruling came while regulators were preparing additional regulations addressing other parts of the 340B program, as reflected in HHS documents in the Federal Register. Those drafts reportedly cover basic program definitions, including the classification of an eligible patient. They were under review by the Office of Management and Budget.
The injunction raises questions about whether the government will publish those drafts for public comment. Regulators may need to reassess their legal approach after the ruling, especially if the proposed rules rely on interpretations that could face a similar objection about agency authority.
Industry stakeholders are watching for changes in the government’s approach to the discount program. The ruling does not settle every issue involving 340B administration, including matters addressed in HHS Office of Inspector General reports and publications. It does, however, limit HRSA’s ability to expand access to discounts by interpreting the orphan drug exception beyond the authority Congress provided.
For now, the blocked rule cannot impose the disputed pricing treatment. Any further change to this part of the 340B program must remain within the boundaries established by Congress.